A prospective randomized safety trial of celecoxib for treatment of preterm labor

Catherine S. Stika*, Gilad A. Gross, Gustavo Leguizamon, Susan Gerber, Roni Levy, Amit Mathur, Lisa M. Bernhard, D. Michael Nelson, Yoel Sadovsky

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

95 Scopus citations


OBJECTIVE: We compared the safety of celecoxib, a selective cyclo-oxygenase-2 inhibitor, with the safety of the nonselective cyclo-oxygenase inhibitor indomethacin, when it was administered for treatment of pre-term labor. STUDY DESIGN: In a randomized, double-blind, placebo-controlled trial, 24 pregnant women in preterm labor at 24 to 34 weeks of gestation received either indomethacin or celecoxib for 48 hours. Clinical assessment, fetal sonography, and Doppler blood flow studies of the fetal ductus arteriosus were performed daily. RESULTS: Mean maximum ductal flow velocity was significantly elevated over baseline (82.9 ± 4.6 cm/s vs 111.14 ± 14.3 cm/s; P = .02) after 24 hours of indomethacin, but not celecoxib. Both medications were associated with a transient decrease in amniotic fluid volume, with a greater effect by indomethacin. The medications were equally effective in the maintenance of tocolysis. There were no significant maternal or neonatal adverse events. CONCLUSION: In this initial evaluation, the safety of short-term celecoxib in women with preterm labor was superior to that of indomethacin.

Original languageEnglish (US)
Pages (from-to)653-660
Number of pages8
JournalAmerican journal of obstetrics and gynecology
Issue number3
StatePublished - Sep 2002


  • Celecoxib
  • Cyclo-oxygenase
  • Indomethacin
  • Preterm labor

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'A prospective randomized safety trial of celecoxib for treatment of preterm labor'. Together they form a unique fingerprint.

Cite this